$240.00
Description
pharmacological properties
Mircera's drug belongs to the pharmacological group of drugs, the purpose of which is to stimulate erythro and leukopoiesis. This is a synthetic drug, which is a new generation of long-acting hematopoietin activators. The main active ingredient of the drug is methoxy polyethylene glycol-epoetin beta.
Mircera medication has a stimulating effect on the process of hematopoiesis, during which erythrocytes are formed. The process of formation of erythrocytes occurs in the kidneys, so the action of the drug extends, first of all, to this organ. The drug effectively combats the signs of anemia in kidney disease, normalizing hemoglobin levels.
Composition and form of release of Mircera
The drug Mircera is available in the form of a soluble liquid with a light yellow tint, which is injected intravenously or under the patient's skin by injection. Mircera contains the following components:
- methoxypolyethyleneglycol-Epoetin beta,
- alpha-amino acid containing aliphatic sulfur,
- mannitol,
- sodium salt of sulfuric acid,
- sodium phosphate, dissolved in water,
- plurnic,
- Dilute Hydrogen Chloride,
- purified water.
The drug is sold in vials in the form of a syringe of 0.3 ml. The package contains instructions, a needle for an injection and the solution itself with the drug.
Mircera application method and characteristics
Once in the patient's body, the drug has a long exposure period, so the frequency of injections should not be more than once a month. The drug is prescribed only by the attending physician after conducting all necessary examinations of the patient, collecting evidence and establishing an accurate anamnesis. Injections should also be given only by the attending physician under specially selected conditions. The drug is sterile, no preservatives are added.The drug, ready for injection, should have a yellowish tint or be transparent, without precipitation. Before injection, the drug should be warmed to room temperature, if it was previously in the refrigerator. The drug with the solution retains its properties and can be used for a month at a temperature not higher than 30 C. After a month, the drug can not be used and must be disposed of. Each bottle can be used only once, after which the remaining funds are thrown away. Do not shake the tube before use. It is necessary to comply with all rules and regulations for storing the drug specified in the current instructions for use. The drug Mircera is used for injections into the vein and under the skin. If the medicine is injected under the skin, then the injection should be in the region of the shoulder, abdomen, or thigh. When taking a course with drugs, you need to monitor hemoglobin.
The duration of the course and the recommended dose of Mircera are prescribed by the attending physician, taking into account the clinical picture of the disease and the individual characteristics of the patient. The decision to cancel the drug, as well as to adjust the dosage, is also made by the attending physician, who monitors the patient's condition throughout the duration of therapy. If the injection is missed for any reason, then it should be delivered as soon as possible after the jump, and then follow the schedule. You should not prescribe Mircera's drug to children under 18 years of age, since there is no exact data on the effect of the components of the drug on a growing and developing organism. Elderly people, patients with liver disease do not need adjustment of dose or duration of treatment. Recommendations for the use of Mircera drugs:
- remove the medicine bottle from the container,
- wash your hands thoroughly and treat with an antiseptic,
- check the tube for damage and damage to integrity,
- remove the protective coating from the vial packaging and draw the solution itself into the syringe,
- take out the individual plastic package with the needle and open it carefully,
- remove the tip of the bottle,
- Carefully insert the needle into the vial of solution.
The medicine can be injected under the skin or into a vein. It is necessary to carefully choose the site of administration of the drug. It is possible to give injections with a solution of the drug in the shoulder region, the front part of the abdomen, without affecting the umbilical region, or the femoral region. Avoid sticking the needle into moles, scars, scars, irritation, bruises, swelling. The injection site must be changed, you cannot inject twice in one place. Before the injection, the injection site is treated with a special disinfectant solution to prevent infection from entering through the puncture site. After the injection, the injection site is also treated and, if necessary, a patch is applied to the wound. Mircera may only be administered by medical personnel with the appropriate qualifications and therapeutic experience.
Mircera's analogs
Epoetinum beta and Methoxypolyaethylenglycolum-epoetinum beta are analogs of the drug Mircera in composition and pharmacological effects.
Erythropoietin (EPO) is a glycoprotein hormone cytokine, the main regulator of erythropoiesis, which stimulates the formation of red blood cells from late progenitor cells (binds to erythropoietin-sensitive receptors, found primarily on erythroblasts). , and promotes the active proliferation of blast cells) and increases the release of reuluticms. One of the most difficult to detect doping is erythropoietin doping.
Erythropoietin belongs to the group – peptide hormones.The convenience of its use lies in the fact that it can cause an increase in the number of red blood cells in the blood and increase the oxygen capacity of the blood. Consequently, more oxygen can be delivered to the tissues (especially muscle!), which increases the efficiency of the body.
Mircera (methoxy polyethylene glycol-epoetin beta) – basically this substance is no different from the previous erythropoietins, with the exception of polyethylene glycol bound to the structure of the drug, which contributes to a longer half-life: Mircera is in the body 6 times longer longer than darbpoetin-alpha and 20 times longer than epoetin, creating the potential for long intervals between drug injections.
All EPO preparations are used according to the same scheme, doses are 50-300 U per kg of weight. The result becomes noticeable after two weeks of use. Most experts are inclined to believe that the drug should not be used for more than six weeks.
Erythropoietin doping is actively used in cyclic sports with a predominant manifestation of endurance (running, swimming, cross-country skiing, speed skating, all kinds of rowing, cycling and others), when the same movement is repeated many times, it is consumed a lot of energy, and the work itself is carried out at a very high intensity.
